Who
Roger Jeffs
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Liquidia; Director, Axsome Therapeutics; Director, Albireo Pharma; Director, Dova Pharmaceuticals; Director, Axovant Sciences; Director, Sangamo Therapeutics; President & Co-CEO, United Therapeutics.
In numbers
- Trades disclosed
- 1,205
- Buys
- 10
- Sells
- 270
- Bought
- $2.6M
- Sold
- $252.4M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 5 Jan 2005
- Last trade
- 12 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Oct 2026filed 13 Oct 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $933K32,744 at $28.48 | filing |
| 9 Oct 2026filed 13 Oct 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code M | —13,833 | filing |
| 9 Oct 2026filed 13 Oct 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code M | —14,333 | filing |
| 9 Oct 2026filed 13 Oct 2026 | LQDA Liquidiaoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,833 at $0.00 | filing |
| 9 Oct 2026filed 13 Oct 2026 | LQDA Liquidiaoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,333 at $0.00 | filing |
| 13 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $179K2,505 at $71.39 | filing |
| 13 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $2.3M32,744 at $71.52 | filing |
| 13 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $179K2,505 at $71.39 | filing |
| 13 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Sold | $2.3M32,744 at $71.52 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code M | —13,834 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code M | —14,333 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA Liquidiaoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,834 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA Liquidiaoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,333 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA Liquidiaoption or derivative · Biotechnology | SEC FORM 4 Code M | —13,834 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA Liquidiaoption or derivative · Biotechnology | SEC FORM 4 Code M | —14,333 at $0.00 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code M | —13,834 | filing |
| 10 Jul 2026filed 14 Jul 2026 | LQDA LiquidiaBiotechnology | SEC FORM 4 Code M | —14,333 | filing |
| 11 Jun 2026filed 11 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $71K286 at $249.12 | filing |
| 11 Jun 2026filed 11 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $71K286 at $249.12 | filing |
| 10 Jun 2026filed 11 Jun 2026 | AXSM Axsome TherapeuticsBiotechnology | SEC FORM 4 Sold | $70K286 at $246.18 | filing |
The newest 500 lines are listed; the numbers count every line.
News
Liquidia (NASDAQ:LQDA) Stock Sees Heavy Call Option BuyingLQDA · dailypolitical.com · 14 Oct 2026Insider Selling: Liquidia (NASDAQ:LQDA) General Counsel Sells $389,948.16 in StockLQDA · themarketsdaily.com · 14 Oct 2026Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAHLQDA · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Roger Jeffs; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.